Fundraising Fox迪哲医药 (Dizal Pharma)
3 known investors
Find your way into 迪哲医药 (Dizal Pharma)
Sign up to see every warm intro you have to 迪哲医药 (Dizal Pharma)
- Paths you didn't know you had: your email and LinkedIn already hold routes to the 迪哲医药 (Dizal Pharma) team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Innovative biopharma company focused on cancer and immune disease therapies (SHSE: 688192).
Investors · 3
Related companies · 5
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
TargetedoncTargeted Oncology is a medical news and education publication for oncologists and cancer care professionals, covering clinical trial data, FDA approvals, treatment guidelines, and expert commentary across cancer types. It delivers conference coverage, podcasts, videos, and short-form content focused on precision oncology and targeted cancer therapies.
ZentalisZentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.
CPV vignettesThe American Journal of Managed Care (AJMC) is a medical media outlet publishing news, research coverage, and conference reporting on managed care, drug pricing, clinical trials, and health policy. Its content serves healthcare professionals, payers, and managed care decision-makers, including a Center on Health Equity & Access.
Dialectic TherapeuticsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Companies working in the same space as 迪哲医药 (Dizal Pharma).
Frequently asked questions
- What does 迪哲医药 (Dizal Pharma) do?
- Innovative biopharma company focused on cancer and immune disease therapies (SHSE: 688192).
- Who are 迪哲医药 (Dizal Pharma)'s investors?
- 迪哲医药 (Dizal Pharma)'s investors include HongShan Capital Group, LAV, Lilly Asia Ventures.